SWI QuickPicks Portfolio Up 19%
SWI QuickPicks Portfolio Up 19%
Marina del Rey, CA - June 8, 2016.  SWI today publishes its June 2016 QuickPicks Performance Report, allowing our subscribers to keep track of our performance. In addition to adding three companies to the portfolio last week, we have initiated coverage of two new stocks with this report and we have removed Cara Therapeutics (CARA), Navios Maritime Acquisition (NNA) and Merus Labs (MSLI) from the portfolio.

The SWI portfolio is up nineteen percent (19%) since inception compared with eight percent (8%) during the same period of time for the S&P.
Headquartered in  Tucson, Arizona , HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of RNA assets that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at  www.htgmolecular.com
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. Additional information on the Company can be found at www.anthera.com
Rainer Poertner - Chief Analyst
 S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI is not holding any positions in any of the stocks covered in this report and has not been compensated for this publication . The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.